Pepsales, an AI-powered SaaS platform that caters to sales teams, has successfully raised $1.1 million in a pre-series funding round. Led by Chirate Ventures, the funding round also saw participation from prominent angel investors in the Bay Area, as well as founders and CXOs from India’s vibrant startup ecosystem. The fresh capital will help Pepsales scale its operations and advance its AI-driven solutions for B2B SaaS companies.

Founded in 2023, Pepsales leverages artificial intelligence and machine learning to create personalised product demonstrations for potential buyers in the B2B SaaS sector. The platform aims to transform the way sales teams interact with customers by providing tailored demos that address specific business needs, ultimately helping SaaS companies close deals more efficiently.

In an interview to CNBC-TV18, Ajay Singh, Co-Founder and CEO of Pepsales, highlighted three key areas of focus for the company’s future growth: enhancing the platform’s AI capabilities, expanding their presence in the US and Indian markets, and building a strong team of product engineers and AI talent.

Singh further revealed that the company has already received significant interest from potential clients. “We have spoken with more than 80 B2B SaaS companies, and all of them are highly interested in trying out our product. Currently, we are working with close to 10 companies, but we are ramping up our product engineering and customer service functions to onboard more clients who have signed up,” Singh said.

Singh emphasised that the US and India will be their primary target markets over the next two years. “The US is a large market for B2B SaaS companies, particularly in sectors like marketing automation, sales automation, and cybersecurity. India, too, has emerged as a key market, thanks to the success of companies like Freshworks and Zoho,” Singh noted.

Additionally, Ahammune Biosciences, a clinical stage therapeutics company working towards creating new ways to treat and cure skin diseases, has raised a Series A funding round of $5 million led by Pi Ventures. The fresh funds raised will be used to conduct phase II human clinical trials for its drug candidate for vitiligo. CNBC-TV18 spoke with Dr Parul Ganju, CEO of Ahammune Biosciences to understand how the company plans to commercialise the drug.

Watch accompanying video for more.